Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) EBITDA (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed EBITDA for 13 consecutive years, with -$1.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA fell 329.12% year-over-year to -$1.5 million, compared with a TTM value of -$6.5 million through Sep 2025, down 52.09%, and an annual FY2024 reading of -$6.7 million, down 67.69% over the prior year.
  • EBITDA was -$1.5 million for Q3 2025 at Sunshine Biopharma, down from -$686277.0 in the prior quarter.
  • Across five years, EBITDA topped out at $661452.0 in Q4 2021 and bottomed at -$23.3 million in Q4 2022.
  • Average EBITDA over 5 years is -$2.8 million, with a median of -$1.3 million recorded in 2024.
  • Peak annual rise in EBITDA hit 161.11% in 2021, while the deepest fall reached 6371.96% in 2021.
  • Year by year, EBITDA stood at $661452.0 in 2021, then crashed by 3618.1% to -$23.3 million in 2022, then skyrocketed by 96.74% to -$758468.0 in 2023, then tumbled by 316.2% to -$3.2 million in 2024, then soared by 52.94% to -$1.5 million in 2025.
  • Business Quant data shows EBITDA for SBFM at -$1.5 million in Q3 2025, -$686277.0 in Q2 2025, and -$1.2 million in Q1 2025.